Replication Kinetics, Cell Tropism, and Associated Immune Responses in SARS-CoV-2- and H5N1 Virus-Infected Human Induced Pluripotent Stem Cell-Derived Neural Models

Lisa Bauer, Bas Lendemeijer, Lonneke Leijten, Carmen W. E. Embregts, Barry Rockx, Steven A. Kushner, Femke M. S. de Vrij, Debby van Riel

ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with a wide variety of neurological complications. Even though SARS-CoV-2 is rarely detected in the central nervous system (CNS) or cerebrospinal fluid, evidence is accumulating that SARS-CoV-2 might enter the CNS via the olfactory nerve. However, what happens after SARS-CoV-2 enters the CNS is poorly understood. Therefore, we investigated the replication kinetics, cell tropism, and associated immune responses of SARS-CoV-2 infection in different types of neural cultures derived from human induced pluripotent stem cells (hiPSCs). SARS-CoV-2 was compared to the neurotropic and highly pathogenic H5N1 influenza A virus. SARS-CoV-2 infected a minority of individual mature neurons, without subsequent virus replication and spread, despite angiotensin-converting enzyme 2 (ACE2), transmembrane protease serine 2 (TMPRSS2), and neuropilin-1 (NPR1) expression in all cultures. However, this sparse infection did result in the production of type III interferons and interleukin-8 (IL-8). In contrast, H5N1 virus replicated and spread very efficiently in all cell types in all cultures. Taken together, our findings support the hypothesis that neurological complications might result from local immune responses triggered by virus invasion, rather than abundant SARS-CoV-2 replication in the CNS.

IMPORTANCE
Infections with the recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are often associated with neurological complications. Evidence suggests that SARS-CoV-2 enters the brain via the olfactory nerve; however, SARS-CoV-2 is only rarely detected in the central nervous system of COVID-19 patients. Here, we show that SARS-CoV-2 is able to infect neurons of human iPSC neural cultures but that this infection is abortive and does not result in virus spread to other cells. However, infection of neural cultures did result in the production of type III interferon and IL-8. In contrast, H5N1 virus replicated and spread very efficiently in all cell types in all cultures. Taken together, our findings support the hypothesis that neurological complications might result from local immune responses triggered by virus invasion, rather than abundant SARS-CoV-2 replication in the CNS.

KEYWORDS
neurotropism, hiPSC neurons, coronavirus, SARS-CoV-2, COVID-19, influenza A virus, H5N1 virus, IL-8, interferon, influenza virus

Neurological manifestations are present in a substantial proportion of patients suffering from the respiratory coronavirus disease 2019 (COVID-19). Symptoms comprise loss of smell (anosmia), loss of taste (hypogeusia), headache, fatigue, nausea, and vomiting (1–3). Additionally, more severe neurological complications such as seizures, confusion, cerebrovascular injury, stroke, encephalitis, encephalopathies, and altered mental status are being increasingly reported in hospitalized patients (4–6).
It remains to be established whether the reported neurological manifestations are a direct consequence of local invasion by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into the central nervous system (CNS), an indirect consequence of the associated systemic immune responses, or a combination of the two. In human and animal models, it has been shown that SARS-CoV-2 is able to replicate in the olfactory mucosa (7, 8), suggesting that the olfactory nerve could function as an important route of entry into the CNS (9), as observed previously for other respiratory viruses (10). Postmortem brain tissue analyses of fatal COVID-19 cases have revealed mild neuropathological changes which might be related to hypoxia, as well as pronounced neuro-inflammation in different regions of the brain (11). In the majority of cases, neither SARS-CoV-2 viral RNA, nor virus antigen, could be detected in the CNS (5, 12). In line with this, SARS-CoV-2 viral RNA has rarely been detected in the cerebrospinal fluid (CSF) of COVID-19 patients with neurological symptoms (13–15). Together, this suggests that SARS-CoV-2 might enter the CNS but be unable to replicate there efficiently.

In the brain, viruses encounter a variety of different cell types such as neurons, astrocytes, and microglia. Investigations of CNS cell-type-specific infection of SARS-CoV-2 have been inconsistent (16–23). Most studies have investigated virus replication by the detection of viral RNA but have not reported whether infectious progeny viruses are produced during the course of infection. In order to investigate replication efficiency, cell tropism, and associated immune responses of SARS-CoV-2 infection in cells of the CNS, we infected different types of human neural cultures. These cultures were differentiated from human induced pluripotent stem cells (hiPSCs) along a variety of different neural lineage specifications, which provided a unique and flexible platform to study the neurotropism of viruses in vitro. Specifically, we directed hiPSC colonies toward neural progenitor cells (NPCs) via an embryoid body stage and subsequently differentiated NPCs to mature neural networks (24). In addition, we also utilized a rapid neuronal differentiation protocol based on forced overexpression of the transcription factor Ngn2 in hiPSCs (Fig. 1A) (25, 26) to generate a pure population of neurons that we cocultured with hiPSC-derived astrocytes. Using these specified CNS cell types, we directly compared the characteristics of SARS-CoV-2 infection with the highly pathogenic H5N1 influenza A virus, a virus with zoonotic potential which is known to efficiently replicate in neural cells in vivo (27–32) and in vitro (33–36).

**RESULTS**

**SARS-CoV-2 does not replicate efficiently in hiPSC-derived neural cell types, despite the presence of ACE2, TMPRSS2, and NRP1.** To investigate the replication efficiency of SARS-CoV-2, we utilized hiPSC-derived NPCs and differentiated these to mature forebrain cortical neural cultures using a previously published protocol (24) (Fig. 1A; see also Fig. S1 in the supplemental material). The resulting cultures contain a mix of electrically active neurons, astrocytes, and progenitors. Pure NPC and mixed mature neural network cultures were infected with SARS-CoV-2 and H5N1 virus at a multiplicity of infection (MOI) of 0.1 and 0.5. At 2, 6, 24, 48, and 72 h postinfection (hpi), infectious virus titers in the supernatants were determined by endpoint titration. In contrast to H5N1 virus, no productive infection in SARS-CoV-2-inoculated NPC and mature neural network cultures was detected (Fig. 1B and C). However, in one out of 3 experiments we observed an increase in virus titers at 72 h postinfection, which explains the small increase in virus titer in the mature neural network cultures. As an alternative to the laborious and time-consuming differentiation of mature neural networks through embryoid bodies and NPC stages, we also employed an established rapid differentiation protocol that yields a pure culture of iPSC-derived glutamatergic cortical neurons by overexpressing the transcription factor neurogenin-2 (Ngn2) (25). We further supplemented the Ngn2-induced neurons with hiPSC-derived astrocytes to support their survival and maturation. The final Ngn2 cocultures contain astrocytes and functional forebrain cortical neurons that form synapses (Fig. 1A and Fig. S1). SARS-CoV-2 did not replicate efficiently in the Ngn2 cocultures, in contrast to H5N1
SARS-CoV-2 and H5N1 in hiPSC-Derived Neural Cultures

FIG 1 SARS-CoV-2 does not replicate in hiPSC-derived neural (co-)cultures in contrast to H5N1 virus. (A) A schematic depiction of the different hiPSC-derived differentiation strategies of the neural cultures. hiPSCs are differentiated into neural progenitor cells (NPCs) and subsequently into mixed neural network cultures containing mixed neurons and astrocytes. Alternatively, hiPSCs are differentiated into excitatory neurons by inducing overexpression of Ngn2; these are grown in a coculture with hiPSC-derived astrocytes. (B to D) Growth kinetics of SARS-CoV-2 or H5N1 virus, in hiPSC-derived NPCs (B), mature neural networks (C), or Ngn2 cocultures (D) using an MOI of 0.1 and 0.5. (E and F) As positive controls, MDCK (E) and VeroE6 (F) cells were infected with H5N1 virus or SARS-CoV-2, respectively. Data represent mean ± standard deviation (SD) from three independent experiments. Every growth curve was performed in either biological duplicates or triplicates. (G) Presence of the host factors angiotensin-converting enzyme 2 (ACE2), transmembrane protease serine 2 (TMPRSS2), and neuropilin-1 (NRP1) of the neural cultures was determined with PCR. As controls for the expression of ACE2 and TMPRSS2, bronchus-bronchiole organoids were used. The uncropped agarose gels are displayed in Fig. S2.

virus (Fig. 1D). As a positive control for virus replication, VeroE6 and MDCK cells were infected with SARS-CoV-2 and H5N1 virus, respectively (Fig. 1E and F).

Next, we evaluated the presence of important SARS-CoV-2 entry factors, such as angiotensin-converting enzyme 2 (ACE2), transmembrane protease serine 2 (TMPRSS2), and neuropilin-1 (NRP1). In all cultures, there was clear evidence for ACE2, TMPRSS2,
and NRP1 expression, suggesting cellular susceptibility to SARS-CoV-2 infection (Fig. 1G and Fig. S2).

**SARS-CoV-2 infects MAP2-expressing neurons and does not induce cleavage of caspase-3.** To determine whether SARS-CoV-2 was able to infect individual cells, we stained for virus nucleocapsid protein (NP) 24 and 72 hpi with an MOI of 0.5. SARS-CoV-2 sparsely infected cells in neural cultures at 24 and 72 hpi. Infection was observed in single scattered MAP2+ neurons (Fig. 2A and B and Fig. S3A and B). In one experiment, we identified a cluster of MAP2+ cells that stained positively for SARS-CoV-2 NP at 72 hpi (Fig. S4A). In the Ngn2 cocultures, we were able to detect only MAP2+/NEUN+ neurons positive for SARS-CoV-2 NP, suggesting that SARS-CoV-2 infects only mature neurons and does so only sparsely (Fig. S4B). We found no convincing evidence of SARS-CoV-2 NP+ cells among SOX2+ NPCs or glial fibrillary acidic protein-positive (GFAP+) astrocytes (Fig. 2A to C). In contrast, H5N1 virus abundantly infected SOX2+ NPCs, GFAP+ astrocytes, and MAP2+ neurons (Fig. 2A to C).

Next, despite the fact that there was no morphological evidence for cell death in the SARS-CoV-2-infected cultures, we wanted to investigate whether SARS-CoV-2 infection induced apoptosis in SARS-CoV-2 NP+ neurons. Therefore, we infected Ngn2 cocultures with SARS-CoV-2 and stained for cleaved caspase-3, an apoptosis marker. We again observed that SARS-CoV-2 infected only MAP2+ neurons. Neurons expressing SARS-CoV-2 NP did not show accumulation of cleaved caspase-3 (Fig. 3A and B and Fig. S4C).

**SARS-CoV-2 infection induces IFN-λ2/3 and IL-8.** To determine the immune response of the neural cultures toward SARS-CoV-2 and H5N1 virus infection, we measured a panel of antiviral cytokines in the supernatant of infected neural cultures at 24 and 72 h postinfection (Fig. 4). Even though SARS-CoV-2 infection was scarce, IFN-λ2/3 was induced in both the mixed neural culture and Ngn2 cocultures but not in NPC cultures. Increased secretion of interleukin-8 (IL-8) was observed in NPC cultures, mixed neural culture, and Ngn2 cocultures. H5N1 virus infection induced both type III IFN IFN-λ1 and IFN-λ2/3 in mixed neural cultures and Ngn2 cocultures, but not among NPCs. Furthermore, increased levels of IP-10 were detected only in the H5N1 virus-infected neural cultures. Similarly to SARS-CoV2, H5N1 virus was also able to induce IL-8 in all neural cultures. Neither SARS-CoV-2 nor H5N1 virus infection induced type I interferon (IFN-α/IFN-β) or type II IFN (IFN-γ) or other cytokines such as IL-1b, tumor necrosis factor alpha (TNF-α), IL-12p70, granulocyte-macrophage colony-stimulating factor (GM-CSF), or IL-10 (Fig. S5).

**DISCUSSION**

SARS-CoV-2 replicated poorly in all three types of hiPSC-derived neural cultures used in our experiments, which contrasts largely with H5N1 virus, which replicated efficiently to high titers. Even though important entry factors for SARS-CoV-2 are expressed in all of the cultures used, SARS-CoV-2 infected a very small proportion of cells without evidence of subsequent spread. Additionally, we did not observe SARS-CoV-2-induced neuronal cell death, indicated by a lack of colabeling with apoptosis marker cleaved caspase 3 in SARS-CoV-2 NP+ neurons. However, SARS-CoV-2 infection did induce type III IFN and IL-8 production.

Evidence is accumulating that SARS-CoV-2 enters the CNS via the olfactory nerve (7–9), a pathway that is also used by influenza A viruses to enter the CNS in many mammals including humans (10, 37). H5N1 virus spreads efficiently to the CNS via the olfactory nerve in experimentally inoculated ferrets and subsequently replicates very efficiently in the CNS (27, 29, 38). Unlike H5N1 virus infection, SARS-CoV-2 is rarely detected in the CNS of fatal COVID-19 patients or experimentally inoculated animals (11–15). In addition, only a few case reports of SARS-CoV-2-induced encephalitis have been reported (39, 40). *In vitro* studies have mainly focused on the ability of SARS-CoV-2 to infect cells of the CNS based on the detection of viral RNA or viral antigen (18, 19, 22, 23, 41), but not many have investigated replication efficiency in time by measuring infectious virus titers (17). So far, several studies showed limited infection of neurons in...
hiPSC-derived brain organoids (22) and BrainSpheres (19), without efficient SARS-CoV-2 replication. So far, only efficient replication has been shown in choroid plexus organoids, especially within choroid plexus epithelium cells (17, 23). Altogether, these observations are consistent with our findings of poor SARS-CoV-2 replication in hiPSC-derived NPCs, neurons, and astrocytes and support a pathophysiological model whereby SARS-CoV-2 invades the CNS but does not replicate efficiently in CNS cell types. However, one caveat of our study is that other cells such as microglia, 

**FIG 2** SARS-CoV-2 infects MAP2+ neurons. Mixed neural network cultures (bar = 100 μm) (A), Ngn2 cocultures (bar = 100 μm) (B), and NPCs (bar = 50 μm) (C) were infected at an MOI of 0.5 with SARS-CoV-2 or H5N1 virus, respectively. At 72 h postinfection, the cells were fixed and stained for the presence of viral antigen (SARS-CoV-2 NP or H5N1 NP in red). MAP2 (cyan) was used as a marker for neurons, astrocytes were identified by staining for glial fibrillary acidic protein (GFAP) (green), and SOX2 (green) was used as a marker for NPCs. Cells were counterstained with DAPI (blue) to visualize the nuclei. Data shown are representative examples from three independent experiments for each culture condition.
oligodendrocytes, and vascular cells (pericytes and endothelial cells) are not present. Therefore, we cannot exclude that SARS-CoV-2 can infect and possibly replicate efficiently in other cells of the CNS or neuronal cell types such as cortical parvalbumin (PV) interneurons or midbrain or hindbrain cell types.

Despite the low proportion of SARS-CoV-2-infected cells and the fact that infection seemed to be abortive in the hiPSC-derived neural cultures, we found evidence for cellular immune activation. In particular, SARS-CoV-2 infection of the neural cultures resulted in the induction of type III IFN, especially IFN-λ2/3, but not type I IFN or type II IFN. This result is in accordance with earlier reports suggesting that SARS-CoV-2 triggers only very mild type I and type II IFN responses but does trigger a robust type III IFN response in cell culture, human airway epithelial cells, ferrets, and SARS-CoV-2-infected individuals (42, 43). In addition, IL-8—a chemotactic factor that attracts leukocytes—was induced in all hiPSC-derived cultures. In lung tissue and peripheral venous blood serum of SARS-CoV-2-infected patients, elevated levels of IL-8 are associated with severe COVID-19 (44–46). Furthermore, IL-8 has been detected in the CSF of SARS-CoV-2 patients who developed encephalitis, which might be induced by the SARS-CoV-2-associated brain immune response, since SARS-CoV-2 RNA could not be detected in the CSF (47). However, how exactly these cytokines contribute to the in vivo neuroinflammatory process and if they are directly triggered by SARS-CoV-2 entry into the CNS need further investigations.

Highly pathogenic H5N1 virus replication has been reported in vivo (27, 29, 31, 32, 48) and in vitro across several different types of human and mouse neural cell cultures (34–36), including the human neuroblastoma line SK-N-SH (26), suggesting this virus is neurotropic. This fits with our observation that H5N1 virus replicates productively and spreads throughout hiPSC-derived neural cultures, infecting NPCs as well as mature neurons and astrocytes. H5N1 virus infection also results in the upregulation of the type III IFN IFN-λ1 and IFN-λ2/3, as well as the antiviral cytokines IL-8 and IP-10. IP-10 has been detected in the CSF of influenza A virus-infected patients and was found to be elevated in the brains of mice experimentally infected with H5N1 virus (49).
However, the mechanism by which H5N1 virus achieves abundant virus replication and robust induction of proneuroinflammatory cytokines remains poorly understood.

Overall, our data fit with clinical findings concerning the ability of these viruses to cause acute CNS disease. In both humans and mammalian animal models, H5N1 virus is able to invade and replicate in cells of the CNS, including neurons, resulting in an acute (meningo-)encephalitis (50–52). In contrast, even though evidence exists that SARS-CoV-2 is able to spread to the CNS via the olfactory nerve (7–9) in SARS-CoV-2-infected patients or experimentally infected animal models, virus is rarely detected in the CNS or associated with acute encephalopathies (13–15).

Altogether, our findings reveal that replication of SARS-CoV-2 in CNS cell types is very limited, which is in contrast to the efficient replication and spread of H5N1 virus. Although the mechanistic pathogenesis of SARS-CoV-2-associated CNS disease remains poorly understood, this study supports the hypothesis that SARS-CoV-2 entry into the CNS and direct injection of a small subset of neurons might trigger inflammation in the brain.

MATERIALS AND METHODS

Cell lines. VeroE6 (ATCC CRL 1586) cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Lonza, Basel, Switzerland) supplemented with 10% fetal calf serum (FCS; Sigma-Aldrich, MO, USA), and 100 μg/ml streptomycin (Lonza, Basel, Switzerland), and 100 μg/ml penicillin (Lonza). Madin-Darby canine kidney (MDCK) cells were maintained in Eagle minimal essential medium (EMEM; Lonza) supplemented with 10% FCS, 100 μg/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine, 1.5 mg/ml sodium bicarbonate (1 mM), 10 mM HEPES, and 0.1 mM nonessential amino acids. All cell lines were grown at 37°C in 5% CO2. The medium was refreshed every 3 to 4 days, and cells were passaged at ≥90% confluence with the use of phosphate-
buffered saline (PBS) and trypsin-EDTA (0.05%). The cells were routinely checked for the presence of mycoplasma.

**Differentiation of iPSCs to NPCs and mature neural cultures.** Human induced pluripotent stem cells (iPSCs) [WTC-11 Coriell no. GM25256, obtained from the Gladstone Institute, San Francisco, CA, USA] were differentiated to NPCs as previously described (2) with slight modifications. After passage 3, NPC cultures were purified using fluorescence-activated cell sorting (FACS) as described previously (53). Briefly, NPCs were detached from the culture plate and resuspended into a single-cell solution. CD184+/CD271+/CD24-/CD2/2% B-27 minus RA supplement was added once to remove proliferating cells from the culture and ensure long-term recordings of the cultures. From day 6 onward, half of the medium was refreshed. Cultures were kept at 37°C and 5% CO2 throughout the differentiation process.

**Differentiation of iPSCs to Ngn2 cocultures.** iPSCs were directly differentiated into excitatory cortical layer 2/3 neurons by forcibly overexpressing the neuronal determinant neurogenin-2 (Ngn2) (25, 26).

**Viruses.** The SARS-CoV-2 isolate (isolate BetaCoV/Munich/BavPat1/2020; European Virus Archive Global no. 026V-03883; kindly provided by C. Drosten) was previously described by Lamers et al. (54, 55). The zoonotic highly pathogenic avian influenza (HPAI) H5N1 virus (A/Indonesia/5/2005) was isolated from a human patient, and the virus was propagated once in embryonated chicken eggs and twice in M. domestica eggs. The SARS-CoV-2 isolate was propagated once in M. domestica eggs.

**Virus titrations.** The SARS-CoV-2 titers were determined by endpoint dilution on VeroE6 cells, calculated according to the method of Kärber (57) and expressed as 50% tissue culture infectious doses/milliliter (TCID₅₀/ml). SARS-CoV-2 virus titers were determined by preparing 10-fold serial dilutions in triplicates of supernatants in Opti-MEM containing GlutaMAX. Dilution supernatants were added to a monolayer of 40,000 VeroE6 cells/well in a 96-well plate and incubated at 37°C. After 5 days, the plates were examined for the presence of cytopathic effect (CPE). Virus titers of HPAI H5N1 were determined by endpoint dilution on MDCK cells as described previously (56). In short, 10-fold serial dilutions of cell supernatants in triplicates were prepared in in Opti-MEM containing GlutaMAX. Dilution supernatants were added to a monolayer of 40,000 VeroE6 cells/well in a 96-well plate and incubated at 37°C. After 5 days, the plates were examined for the presence of cytopathic effect (CPE). Virus titers of HPAI H5N1 were determined by endpoint dilution on MDCK cells as described previously (56). In short, 10-fold serial dilutions of cell supernatants in triplicates were prepared in Opti-MEM containing GlutaMAX. Dilution supernatants were added to a monolayer of 40,000 VeroE6 cells/well in a 96-well plate and incubated at 37°C. After 5 days, the plates were examined for the presence of cytopathic effect (CPE). Virus titers of HPAI H5N1 were determined by endpoint dilution on MDCK cells as described previously (56). In short, 10-fold serial dilutions of cell supernatants in triplicates were prepared in Opti-MEM containing GlutaMAX. Dilution supernatants were added to a monolayer of 40,000 VeroE6 cells/well in a 96-well plate and incubated at 37°C. After 5 days, the plates were examined for the presence of cytopathic effect (CPE). Virus titers of HPAI H5N1 were determined by endpoint dilution on MDCK cells as described previously (56). In short, 10-fold serial dilutions of cell supernatants in triplicates were prepared in Opti-MEM containing GlutaMAX. Dilution supernatants were added to a monolayer of 40,000 VeroE6 cells/well in a 96-well plate and incubated at 37°C. After 5 days, the plates were examined for the presence of cytopathic effect (CPE). Virus titers of HPAI H5N1 were determined by endpoint dilution on MDCK cells as described previously (56). In short, 10-fold serial dilutions of cell supernatants in triplicates were prepared in Opti-MEM containing GlutaMAX. Dilution supernatants were added to a monolayer of 40,000 VeroE6 cells/well in a 96-well plate and incubated at 37°C. After 5 days, the plates were examined for the presence of cytopathic effect (CPE). Virus titers of HPAI H5N1 were determined by endpoint dilution on MDCK cells as described previously (56). In short, 10-fold serial dilutions of cell supernatants in triplicates were prepared in Opti-MEM containing GlutaMAX. Dilution supernatants were added to a monolayer of 40,000 VeroE6 cells/well in a 96-well plate and incubated at 37°C. After 5 days, the plates were examined for the presence of cytopathic effect (CPE). Virus titers of HPAI H5N1 were determined by endpoint dilution on MDCK cells as described previously (56). In short, 10-fold serial dilutions of cell supernatants in triplicates were prepared in Opti-MEM containing GlutaMAX. Dilution supernatants were added to a monolayer of 40,000 VeroE6 cells/well in a 96-well plate and incubated at 37°C. After 5 days, the plates were examined for the presence of cytopathic effect (CPE). Virus titers of HPAI H5N1 were determined by endpoint dilution on MDCK cells as described previously (56). In short, 10-fold serial dilutions of cell supernatants in triplicates were prepared in Opti-MEM containing GlutaMAX. Dilution supernatants were added to a monolayer of 40,000 VeroE6 cells/well in a 96-well plate and incubated at 37°C. After 5 days, the plates were examined for the presence of cytopathic effect (CPE). Virus titers of HPAI H5N1 were determined by endpoint dilution on MDCK cells as described previously (56). In short, 10-fold serial dilutions of cell supernatants in triplicates were prepared in Opti-MEM containing GlutaMAX. Dilution supernatants were added to a monolayer of 40,000 VeroE6 cells/well in a 96-well plate and incubated at 37°C. After 5 days, the plates were examined for the presence of cytopathic effect (CPE). Virus titers of HPAI H5N1 were determined by endpoint dilution on MDCK cells as described previously (56). In short, 10-fold serial dilutions of cell supernatants in triplicates were prepared in Opti-MEM containing GlutaMAX. Dilution supernatants were added to a monolayer of 40,000 VeroE6 cells/well in a 96-well plate and incubated at 37°C. After 5 days, the plates were examined for the presence of cytopathic effect (CPE). Virus titers of HPAI H5N1 were determined by endpoint dilution on MDCK cells as described previously (56). In short, 10-fold serial dilutions of cell supernatants in triplicates were prepared in Opti-MEM containing GlutaMAX. Dilution supernatants were added to a monolayer of 40,000 VeroE6 cells/well in a 96-well plate and incubated at 37°C. After 5 days, the plates were examined for the presence of cytopathic effect (CPE). Virus titers of HPAI H5N1 were determined by endpoint dilution on MDCK cells as described previously (56). In short, 10-fold serial dilutions of cell supernatants in triplicates were prepared in Opti-MEM containing GlutaMAX. Dilution supernatants were added to a monolayer of 40,000 VeroE6 cells/well in a 96-well plate and incubated at 37°C. After 5 days, the plates were examined for the presence of cytopathic effect (CPE). Virus titers of HPAI H5N1 were determined by endpoint dilution on MDCK cells as described previous...
the supernatant was mixed with 75 μl 0.33% turkey red blood cells and incubated for 1 h at 4°C. The titers of infectious virus were calculated according to the method of Kärber (57) and expressed as TCID_{50}/ml. All experiment with infectious SARS-CoV-2 and H5N1 virus were performed in a class II biosafety cabinet under biosafety level 3 (BSL-3) conditions at the Erasmus Medical Center. The initial 1:10 dilution of cell supernatant resulted in a detection limit of 10^{1.5} TCID_{50}/ml.

**Replication kinetic.** Before infection of neural progenitors, network neurons, and Ngn2 neurons, supernatant was removed and cells were infected with SARS-CoV-2 and H5N1 virus at the indicated multiplicity of infection (MOI). As a control for active virus replication, VeroE6 and MDCK cells were infected with SARS-CoV-2 and H5N1 virus, respectively. Before virus infection, the VeroE6 cells were washed with SARS-CoV-2 infection medium (DMEM supplemented with 2% FBS and 100 IU/ml penicillin, 100 μg/ml streptomycin) and MDCK cells were washed with influenza infection medium. After 1 h of incubation at 37°C, the inoculum was removed and replaced with fresh medium and old medium in a 1:1 ratio. After removing the inoculum from VeroE6 and MDCK cells, SARS-CoV-2 infection medium and influenza infection medium, respectively, were added to the cells. At the indicated time points, an aliquot of the supernatant was collected for subsequent virus titration. All experiments were performed in biological triplicates and in either technical duplicates or triplicates.

**PCR validation of ACE2, TMPRSS2, and NRP1 expression.** RNA was isolated from the neural cultures and VeroE6 cells using the High Pure RNA isolation kit (Roche). The concentration of RNA was determined using a NanoDrop spectrophotometer. A 2.5-μg amount of RNA was reverse transcribed into cDNA using the SuperScript III reverse transcriptase (Invitrogen) according to the manufacturer’s protocol. CDNA of bronchus-bronchiole organoids was kindly provided by Anna Z. Mykytyn. The presence of ACE2, TMPRSS2, NRP1, and ACT was evaluated by amplifying these genes with gene-specific primers (Table 2) by PCR. Gene products were visualized on a 2% agarose gel which was stained with SYBR Safe. PCR products of the genes were sequenced to validate that the right product was amplified.

**Multiplexed bead assay for cytokine profiling.** Cytokines were measured using the LEGENDplex human antivirus response panel (BioLegend). The kit was used according to the manufacturer’s manual with an additional fixing step. After adding the SA-PE and performing the washing steps, the supernatant and the beads were fixed with formalin for 15 min at room temperature and washed twice with the provided wash buffer. This ensures that all pathogens are not infectious.

**Immunofluorescent labeling.** Cells were fixed using 4% formalin in PBS and labeled using immunocytochemistry. Primary antibody incubation was performed overnight at 4°C. Secondary antibody incubation was performed for 2 h at room temperature. Both primary and secondary antibody incubations were performed in staining buffer (0.05 M Tris, 0.9% NaCl, 0.25% gelatin, and 0.5% Triton X-100 [Sigma; T8787] in PBS [pH 7.4]). Primary antibodies and their dilutions can be found in Table 3. Secondary antibodies conjugated to Alexa-488, Alexa-647, or Cy3 were used at a dilution of 1:400 (Jackson ImmunoResearch). Nuclei were visualized using 4',6-diamidino-2-phenylindole (DAPI) (ThermoFisher Scientific; D1306). Samples were embedded in Mowiol 4-88 (Sigma-Aldrich; 81381) and imaged using a Zeiss LSM 800 confocal microscope (Oberkochen, Germany).

### Table 2: Gene-specific primers for PCR

| Species | Gene     | Sequence (5'—3') | Annealing temp (°C) | Amplicon (bp) | Reference |
|---------|----------|------------------|---------------------|---------------|-----------|
| Human   | ACE2-FWD | GGGATCAGAGATCGGAAGAAGAAA | 60                | 124           | 1         |
| Human   | ACE2-REV | AGGAGGTCTGAACATCATCAGTG   | 60                | 134           | 1         |
| Human   | b-ACTIN-FWD | CCTGGACTTTCGAGCAAGAG   | 60                | 153           | 1         |
| Human   | b-ACTIN-REV | ACTCCATGCCCCAGGAAGAAAA | 60                | 106           | 1         |
| Human   | TMPRSS2-FWD | AATCGGTTGTGGCGGGCTCTAC | 60                | 187           | 1         |
| Human   | TMPRSS2-REV | CGTAGTCTGGTGGCAAGGATCGTG | 60                | 187           | 1         |
| Human   | NRP1-FWD | GACTGGGAGCTAGAATGGGAG   | 60                | 187           | 1         |
| Human   | NRP1-REV | ATGACCGTGGGCTTTTCTGT    | 60                | 187           | 1         |

### Table 3: Antibodies

| Antibody          | Dilution | Manufacturer, catalogue no.                  |
|-------------------|----------|----------------------------------------------|
| SARS-CoV-2 anti-NP| 1:500    | Sino Biological, 40143-MM05                   |
| SOX2              | 1:250    | Millipore, AB5604                            |
| NEUN              | 1:100    | Merck, ABN78                                 |
| GFAP              | 1:200    | Millipore, AB5804                            |
| MAP2              | 1:200    | Synaptic Systems, 188004                     |
| HSN1 anti-NP      | 1:1,000  | EVL, EBS-I-047, clone Hb65                   |
| Cleaved caspase-3 | 1:100    | Cell Signaling Technologies, 96615           |
| Beta III tubulin (TUJ1) | 1:200 | Millipore, AB9354                            |
| PSD-95            | 1:100    | Thermo Scientific, MA1-046                   |
| Synapsin          | 1:100    | Synaptic Systems, 106 103                    |
| FOXG1             | 1:200    | Abcam, 18259                                 |
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
FIG S1, JPG file, 2.9 MB.
FIG S2, JPG file, 0.8 MB.
FIG S3, JPG file, 2.7 MB.
FIG S4, PDF file, 10.2 MB.
FIG S5, JPG file, 0.9 MB.

ACKNOWLEDGMENTS
We thank Anna Z. Mykytyn and Mart M. Lamers for sharing reagents, cDNA of the airway organoids, and SARS-CoV-2 virus stocks and for technical advice and scientific discussions.

This work was supported by a fellowship to D.V.R. from the Netherlands Organization for Scientific Research (VIDI contract 91718308) and a EUR fellowship. This work was also supported by the Netherlands Organ-on-Chip Initiative, an NWO Gravitation project (024.003.001) funded by the Ministry of Education, Culture and Science of the government of the Netherlands (S.A.K., F.M.S.D.V., B.L.), and by an Erasmus MC Human Disease Model Award to F.M.S.D.V.

We declare no conflict of interest.

REFERENCES
1. Varatharaj A, Thomas N, Ellul MA, Davies NWS, Pollak TA, Tenorio EL, Sultan M, Easton A, Breen G, Zandi M, Coles JP, Manji H, Al-Shahi Salman R, Menon DK, Nicholson TR, Benjamin LA, Carson A, Smith C, Turner MR, Solomon T, Kneen R, Pett SL, Galea I, Thomas RH, Michael BD, Allen C, Archibald N, Arkell J, Arthur-Farraj P, Baker M, Ball H, Bradley-Barker V, Brown Z, Bruno S, Carey L, Carswell C, Chakrabarti A, Choulelon J, Daher M, Davies R, Di Marco Barros R, Dima S, Dunley R, Dutta D, Ellis R, Everett A, Fady J, Fearon P, Fisniku L, Gbinigie I, et al. 2020. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry 7:875–882. https://doi.org/10.1016/S2215-0366(20)30287-X
2. Bryche B, St Albin A, Murri S, Lacôte S, Pulido C, Ar Gouilh M, Lesellier S, Servat A, Wasniewski M, Picard-Meyer E, Monchatre-Leroy E, Volmer R, Rampin O, Le Goff R, Marianneau P, Meunier N. 2020. Massive transient damage of the olfactory epithelium associated with infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters. Brain Behav Immun 89:579–586. https://doi.org/10.1016/j.bbi.2020.06.032.
3. Harapan BN, Yoo HJ. 2021. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J Neurol https://doi.org/10.1007/s00415-021-10406-y.
4. Guadarrama-Ortiz P, Choreño-Parra JA, Sánchez-Martínez CM, Pacheco-Sánchez FJ, Rodríguez-Nava AI, Sánchez-FJ, Rodríguez-Nava AI, Sánchez-Martínez CM, Pacheco-Sánchez FJ, Rodríguez-Nava AI, García-Quintero G. 2020. Neurological and neuropsychiatric aspects of SARS-CoV-2 infection: mechanisms and manifestations. Front Neurol 11:1039. https://doi.org/10.3389/fneur.2020.01039.
5. Solomon IH, Normandin E, Bhattacharyya S, Mukerji SS, Keller K, Ali AS, Adams G, Hornick JI, Padera RF, Jr, Sabeti P. 2020. Neuropathological features of Covid-19. N Engl J Med 383:1177–1179. https://doi.org/10.1056/NEJMoa2001737.
6. Pennisi M, Lanza G, Falciro F, Siretti P, Schioppa M, Alberico D, Ginevra S, Schiavi A, Pellegrini L, Albecka A, Mallery DL, Kellner MJ, Paul D, Carter AP, James LC, Lancaster MA. 2020. SARS-CoV-2 infects the brain choroid plexus and the nervous system: from clinical features to molecular mechanisms. Front Immun 89:579–586. https://doi.org/10.1016/j.bbi.2020.06.032.
7. Zou L, Guo Q, Song T, He J, Yen H-L, Peiris M, Wu J. 2020. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 382:1177–1179. https://doi.org/10.1056/NEJMoa2001737.
8. Sia SF, Yan L-M, Chin AWH, Fung K, Choy K-T, Wong AYL, Kaewpreedee P, Perera RAPM, Poon LLM, Nicholls JM, Peiris M, Yen H-L. 2020. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583:834–838. https://doi.org/10.1038/s41586-020-2342-5.
9. Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, Laue M, Schneider J, Brüning S, Greuel S, Lehmann M, Hassan O, Ashman T, Schumann E, Chua RL, Conrad E, Els R, Stenzel W, Windgassen M, Rößler L, Goebl H-H, Gelderblom HR, Martin H, Nitsche A, Schulz-Schaeffer WJ, Hakroush S, Winkler MS, Tampe B, Scheibe F, Körtvélyessy P, Reinhold D, Siegmund B, Kühl AA, Elekzurtaya S, Horst D, Oesterhelweg L, Tsokos M, Ingold-Höppner B, Stadelmann C, Drosten C, Corman VM, Radbruch H, Heppner FL. 2021. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci 24:168–175. https://doi.org/10.1038/s41593-020-00758-5.
10. Van Riel D, Verdijk R, Kuiken T. 2015. The olfactory nerve: a shortcut for influenza and other viral diseases into the central nervous system. J Pathol 235:277–287. https://doi.org/10.1002/path.4461.
11. Matschke J, Lütgethermann M, Hagel C, Sperhake JP, Schröder AS, Adler C, Mushumba H, Fitzek A, Allweiss L, Dandi M, Dottermusch M, Heinemann A, Pfefferle S, Schwabenland M, Sumner Maguder D, Bonn S, Prinz M, Gerloff C, Püschel K, Krasmann S, Apfelbacher M, Glatzel M. 2020. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol 19:919–929. https://doi.org/10.1016/S1474-4422(20)30308-2.
12. Schurkin L, Roos E, Radonic T, Karbe E, Boeur CS, de Boer HH, de Bree GJ, Bulle EB, Aronica EM, Florquin S, Franzek J, Heunks LM, de Jong MD, Guo L, Du Long R, Lutter R, Molenaar PCG, Neefjes-Borst EA, Niessen HWM, van Noesel CJM, Roelofs JJTH, Smiter EL, Soer EC, Verheij J, Vlaar APJ, Vis W, van der Wel VN, van der Wal AC, van der Valk P, Bugiani M. 2020. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe 1:e290–e292. https://doi.org/10.1016/S2666-5247(20)30144-0.
13. Edén A, Kanberg N, Gostner J, Fuchs D, Hagberg L, Andersson L-M, Lindh M, Price RW, Zetterberg H, Giessel M. 2021. CSF biomarkers in patients with COVID-19 and neurologic symptoms: a case series. Neurology 96: e294–e300. https://doi.org/10.1212/WNL.0000000000010977.
14. Neumann B, Schmidbauer MI, Dimitriades K, Otto S, Knier B, Niesen W-D, Hosp JA, Günther A, Lindemann S, Nagy G, Steinberg T, Linker RA, Hemmer B, Bösel J, PANDEMIC and IGNITE study groups. 2020. Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms. J Neurol Sci 418:117090. https://doi.org/10.1016/j.jns.2020.117090.
15. Destras G, Bal A, Escuret V, Mofrin F, Lina B, Josset L, COVID-Diagnosis HCL Study Group. 2020. Systematic SARS-CoV-2 screening in cerebrospinal fluid during the COVID-19 pandemic. Lancet Microbe 1:e149. https://doi.org/10.1016/S2666-5247(20)30066-5.
16. Dobrindt K, Haagland DA, Seah C, Kassim B, O’Shea CP, Murphy A, Ishikahava M, Fernando MB, Powell SK, Deans PJM, Javidfar B, Peter C, Moller R, Uhl SA, Garcia MF, Kimura M, Iwasawa K, Crary JF, Kotton DN, Takebe T, Huckins LM, tenOever BR, Akbarian S, Brennand KJ. 2021. Common genetic variation in humans impacts in vitro susceptibility to SARS-CoV-2 infection. Stem Cell Rep 16:505–514. https://doi.org/10.1016/j.stemcr.2021.02.010.
17. Pellegrini L, Albecka A, Mallory DL, Kellner MJ, Paul D, Carter AP, James LC, Lancaster MA. 2020. SARS-CoV-2 infects the brain choroid plexus and...
disrupts the blood-CSF barrier in human brain organoids, Cell Stem Cell 27:951–961.e5. https://doi.org/10.1016/j.stem.2020.01.001.

18. Zhang B-Z, Chu H, Han S, Shuai H, Deng J, Hu Y-F, Gong H-R, Lee AC-Y, Zou Z, Yao T, Wu W, Hung IF-N, Chan JF-W, Yuan K-Y, Huang J-D. 2020. SARS-CoV-2 infects human neural progenitor cells and brain organoids. Cell Res 30:928–931. https://doi.org/10.1038/s41422-020-0390-x.

19. Bullen OK, Hogberg HT, Bahadur-Tallbott A, Bishai WR, Hartung T, Keutmann H, Looney MM, Pekosz A, Romero JC, Sillé FCM, Um, P, Smirnova L. 2020. Infectability of human BrainSpheres neurons suggests neurotropism of SARS-CoV-2. ALTEX 37:665–671. https://doi.org/10.14575/altex.20061115.

20. Wang C, Zhang M, Garcia G, Tian E, Cui Q, Chen X, Sun G, Wang J, Arumugaswami V, Shi Y. 2021. ApoE-isofom-dependent SARS-CoV-2 neurotropism and cellular response. Cell Stem Cell 28:331–342.e5. https://doi.org/10.1016/j.stem.2020.12.018.

21. Song E, Zhang C, Israelov B, Lu-Culligan A, Vitees Prado A, Skrabine S, Lu P, Weizman O-E, Liu F, Dai Y, Zigetti-Buck K, Yasumoto Y, Wang G, Castaldi C, Heltke J, Ng E, Wheeler J, Medel Alfajaro M, Levavasseur E, Fontes B, Ravindra NG, Van Dijk D, Mane S, Gunel M, Ring A, Kazim SAJ, Zhang K, Wilen CB, Horvath TI, Plu I, Haiß, Thomas J-L, Louri A, Farhadian SF, Huttner A, Seilhean D, Renier N, Bilguvar K, Iwasaki A. 2021. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med 218: e20201235. https://doi.org/10.1084/jem.20201235.

22. Ramani A, Müller I, Ostermann GN, Gabriel E, Abida-Islam P, Müller-Schubert A, Mariappan A, Goureau O, Gruell H, Walker A, André M, Hauka S, Houwaart T, Dilthey A, Wohlgemuth K, Omran K, Klein F, Wieczorek D, Adams O, Timm J, Korth C, Schaal H, Gopalan Krishnan J. 2020. SARS–CoV-2 targets neurons of 3D human brain organoids. EMBO J 39: e106230. https://doi.org/10.15252/embj.2020106230.

23. Jacob F, Pather SR, Huang W-K, Zhang F, Wong SZH, Zhou H, Cubitt B, Fan W, Chen CZ, Xu M, Pradhan M, Zhang DY, Zheng W, Bang AG, Song H, Carlos de la Torre J, Ming G-L. 2020. Human pluripotent stem cell-derived neuronal and brain organoids reveal SARS-CoV-2 tropism predominate in choroid plexus epithelium. Cell Stem Cell 27:937–950.e9. https://doi.org/10.1016/j.stem.2020.09.016.

24. Gunhanlar N, Shpak G, van der Kroeg M, Coyne-Colomer LA, Munshi ST, Lendemeijer B, Ghazvini M, Dupont C, Hoogendijk WJG, Gribnau J, de Vrij L. 2020. Infectability of human BrainSphere neurons suggests neurotropism of SARS-CoV-2 and model virus infection in human cells and organoids. Cell Stem Cell 27:125–136.e7. https://doi.org/10.1016/j.stem.2020.06.015.

25. Yang L, Han Y, Nilsson-Payant BE, Gupta V, Pian Duan X, Tang X, Jürgen Zhao Z, Jaffré F, Zhang T, Kim TW, Hartschuh O, Redmond D, Houghton S, Liu C, Naji A, Ciceri G, Guttikonda S, Bram Y, Nguyen-DT, Cioffi M, Chandar V, Hoagland DA, Huang X, Yang J, Wang H, Lyden D, Borcuk A, Chen JH, Studer L, Pan FC, Ho DD, tenDever BR, Evans T, Schwartz RE, Chen S. 2020. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell 25:1036.e26. https://doi.org/10.1016/j.stem.2020.04.026.

26. Del Valle DM, Kim-Schulze S, Huang H-H, Beckmann ND, Nirenberg S, Wang TX, Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Kim J, Albrecht RA, tenDever BR. 2020. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181:1036–1045.e9. https://doi.org/10.1016/j.cell.2020.04.026.

27. GeurtsvanKessel CH. 2020. Temporal kinetics of RNAemia and associated systemic cytokines in hospitalized COVID-19 patients. bioRxivhttps://doi.org/10.1101/2020.12.17.423376.

28. Shinya K, Yamada A, Ito T, Otsuki K, Morita T, Takada H, Takada A, Kida H, Umemura T. 2000. Avian influenza H5N1 virus induces cytopath and proinflammatory cytokine responses in human astrocyte and neuronal cell lines. Neuroscience 96:613–623. https://doi.org/10.1016/S0306-4522(00)00239-1.

29. Benameur K, Agarwal A, Auld SC, Butters MP, Webster AS, Ozturk T, Blanco-Melo D, Nilsson-Payant BE, Liu W-C, Uhl S, Hoagland D, Møller R, Duan X, Tang X, Zhu J, Yang L, Han Y, Nilsson-Payant BE, Gupta V, Wang P, Duan X, Tang X, Zhu J, Zou Z, Jaffré F, Zhang T, Kim TW, Hartschuh O, Redmond D, Houghton S, Liu C, Naji A, Ciceri G, Guttikonda S, Bram Y, Nguyen-DTH, Cioffi M, Chandar V, Hoagland DA, Huang X, Yang J, Wang H, Lyden D, Borcuk A, Chen JH, Studer L, Pan FC, Ho DD, tenDever BR, Evans T, Schwartz RE, Chen S. 2022. Human Pluripotent stem cells express CDA1 and reveal SARS-CoV-2 tropism and Model virus infection in human cells and organoids. Cell Stem Cell 28:331.e5. https://doi.org/10.1016/j.stem.2020.10.001.

30. Geurts-van Kessel CH. 2020. Temporal kinetics of RNAemia and associated systemic cytokines in hospitalized COVID-19 patients. bioRxivhttps://doi.org/10.1101/2020.12.17.423376.
Encephalopathy and encephalitis associated with cerebrospinal fluid cytokine alterations and coronavirus disease, Atlanta, Georgia, USA, 2020. Emerg Infect Dis 26:2016–2021. https://doi.org/10.3201/eid2609.202122.

48. Park CH, Matsuda K, Sunden Y, Ninomiya A, Takada A, Ito H, Kimura T, Ochiai K, Kida H, Umemura T. 2003. Persistence of viral RNA segments in the central nervous system of mice after recovery from acute influenza A virus infection. Vet Microbiol 97:259–268. https://doi.org/10.1016/j.vetmic.2003.10.001.

49. Jang H, Boltz D, McClaren J, Pani AK, Smeyne M, Korff A, Webster R, Smeyne RJ. 2012. Inflammatory effects of highly pathogenic H5N1 influenza virus infection in the CNS of mice. J Neurosci 32:1545–1559. https://doi.org/10.1523/JNEUROSCI.5123-11.2012.

50. Kroeze EV, Bauer L, Caliendo V, van Riel D. 2021. In vivo models to study the pathogenesis of extra-respiratory complications of influenza A virus infection. Viruses 13:848. https://doi.org/10.3390/v13050848.

51. Mak GCK, Kwan MY-W, Mok CKP, Lo JYC, Peiris M, Leung CW. 2018. Influenza A(H5N1) virus infection in a child with encephalitis complicated by obstructive hydrocephalus. Clin Infect Dis 66:136–139. https://doi.org/10.1093/cid/cix707.

52. Gambotto A, Barratt-Boyes SM, de Jong MD, Neumann G, Kawaoka Y. 2008. Human infection with highly pathogenic H5N1 influenza virus. Lancet 371:1464–1475. https://doi.org/10.1016/S0140-6736(08)60627-3.

53. Yuan SH, Martin J, Elia J, Flippin J, Paramban R, Heffernan MP, Vidal JG, Mu Y, Killian RL, Israel MA, Emre N, Marsala S, Marsala M, Gage FH, Goldstein LSB, Carson CT. 2011. Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS One 6:e17540. https://doi.org/10.1371/journal.pone.0017540.

54. Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschkof J, Breugem TI, Ravelli RBG, van Schayck JP, Mykytyn AZ, Duimel HQ, van Donselaar E, Rieesebosch S, Kuipers HJH, Schipper D, van de Wetering WJ, de Graaf M, Koopmans M, Cuppen E, Peters PJ, Haagmans BL, Clevers H. 2020. SARS-CoV-2 productively infects human gut enterocytes. Science 350:54. https://doi.org/10.1126/science.abc1669.

55. Lamers MM, Mykytyn AZ, Breugem TI, Wang Y, Wu DC, Rieesebosch S, van den Doel PB, Schipper D, Bestbroer T, Wu NC, Haagmans BL. 2021. Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation. bioRxiv https://doi.org/10.1101/2021.01.22.427802v1.

56. Rimmelzwaan GF, Baars M, Claas ECJ, Österhaus ADME. 1998. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods 74:57–66. https://doi.org/10.1016/S0166-0934(98)00071-8.

57. Kärber G. 1931. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn Schmiedebergs Arch Exp Pathol Pharmacol 162:480–483. https://doi.org/10.1007/BF01863914.